Natixis Advisors, L.P. Regeneron Pharmaceuticals, Inc. Transaction History
Natixis Advisors, L.P.
- $54.1 Billion
- Q1 2025
A detailed history of Natixis Advisors, L.P. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 116,232 shares of REGN stock, worth $65.1 Million. This represents 0.14% of its overall portfolio holdings.
Number of Shares
116,232
Previous 109,938
5.73%
Holding current value
$65.1 Million
Previous $78.3 Million
5.87%
% of portfolio
0.14%
Previous 0.15%
Shares
31 transactions
Others Institutions Holding REGN
# of Institutions
1,431Shares Held
84.9MCall Options Held
1.39MPut Options Held
1.42M-
Vanguard Group Inc Valley Forge, PA9.41MShares$5.27 Billion0.11% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$4.73 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY5.66MShares$3.17 Billion0.28% of portfolio
-
State Street Corp Boston, MA4.79MShares$2.68 Billion0.13% of portfolio
-
Capital International Investors Los Angeles, CA3.99MShares$2.23 Billion0.52% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $60B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...